The lead product under development, VT-X7, is a drug-device combination product designed for local antibiotic delivery to treat infected joint prosthesis. If granted FDA approval, VT-X7 would become the first therapy specifically indicated for the treatment of periprosthetic joint infection (PJI). VT-X7 has undergone extensive pre-clinical development and completed two Phase 2 clinical trials where all primary endpoints were successfully met.